Samsung Bioepis has become the first company to get European Commission (EC) approval for biosimilar versions of three anti-TNF-α blockbusters.
The company, which is a joint venture between Samsung BioLogics and US biotech firm Biogen (Nasdaq: BIIB), has announced the approval of Imraldi , a biosimilar referencing Humira (adalimumab), a mega blockbuster biologic marketed by US drugmaker AbbVie (NYSE: ABBV).
"Our agile biologics development platform has allowed us to develop approved biosimilars in less time at lower cost"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze